KOSDAQBiotech & Pharma475830

Orum Therapeutics

₩13,380▼ 0.30%2026-11-18 close
Market Cap
₩291.1B
Turnover
₩1B
Volume
70K
Shares out.
21.8M
PER
21.6×
PBR
1.7×
EPS
₩620
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

After the BMS Halt, Orum's Own Pipeline Is the Test

With the BMS program discontinued and no further milestones payable, Orum's next test is whether its own DAC pipeline can build an earnings base after operating losses since 2024.

  1. 1

    On September 17, 2026, Orum disclosed that Bristol Myers Squibb (BMS) had decided to discontinue ORM-6151 (BMS-986497), ending the asset transfer agreement. The USD 100 million upfront payment need not be returned, but up to USD 80 million in further milestones is no longer receivable.

  2. 2

    Operating losses on a regulatory-filing basis were KRW 8.34 billion in 2024 and KRW 51.8 billion in 2025, two consecutive loss years. Operating losses have continued for five straight quarters from the third quarter of 2025 through the third quarter of 2026.

  3. 3

    Controlling-shareholder net income of KRW 63.4 billion in the second quarter of 2026 was a single profitable quarter amid continued operating losses. The four-quarter total of KRW 13.7 billion relies heavily on that one quarter.

  4. 4

    On September 18, 2026, the share price fell 29.96% from the prior close, hitting the daily limit-down level. The market absorbed the shock on the same day, before any full-year filing reflected the program's end.

  5. 5

    DAC candidate ORM-1153 has received an Investigational New Drug (IND) approval from the US FDA, and the conversion period for the convertible preferred shares starts on January 14, 2027.

02

Business structure

Orum Therapeutics, founded in 2016 and based in Daejeon, builds antibody-degrader conjugates (DAC) that link a targeted protein degrader to an antibody through a linker.

The company develops oncology and immuno-oncology drugs on its proprietary TPD² platform and operates a Boston research unit, so Korean and US research teams collaborate.

Its approach degrades target proteins instead of delivering the cytotoxic payloads used in conventional antibody-drug conjugates (ADC), which is the main point of differentiation.

Revenue depends on B2B licensing deals with global pharmaceutical companies, where upfront payments, milestones and royalties are the key financial items.

The representative deal is the October 2023 agreement with BMS for ORM-6151, with a total value of USD 180 million, of which USD 100 million was received as an upfront payment. BMS ended the program in September 2026 after reviewing clinical data.

The blood cancer candidate ORM-1153 has IND clearance from the US FDA, while the solid tumor candidate ORM-5029 was halted during Phase 1 because of liver toxicity.

Among competitors, DAC is drawing attention as a next-generation antibody technology, and Roche's technology collaboration with DAC developer C4 Therapeutics in April 2026 shows that large pharma interest continues.

Annual revenue, however, fell from KRW 135.4 billion in 2023 to KRW 23.56 million in 2025, so the business model is highly sensitive to the timing of licensing deals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15,889,734-₩13.9B−87721.7%
2025Q4₩558,176-₩18.3B−3270387.0%
2026Q1₩0-₩18.1B—
2026Q2₩24,105,273-₩15.4B−63691.0%
2026Q3₩24,853,286-₩16.1B−64704.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩135.4B₩95.6B₩68.2B70.6%—−388.0%
2024₩20.9B-₩8.3B-₩5.7B−39.9%−4.7%26.3%
2025₩23,564,233-₩51.8B-₩42B−219651.4%−32.1%29.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a regulatory-filing basis, revenue went from KRW 135.4 billion in 2023 to KRW 20.9 billion in 2024, a decrease of 84.6% from the prior year, and then to KRW 23.56 million in 2025, a decrease of 99.9%.

Revenue declined for two consecutive years from 2024 to 2025, with 2023 the largest year and 2025 the smallest of the three years.

The 2023 figure falls in the same year as the October 2023 BMS agreement, which suggests deal income was concentrated in that year, though revenue recognition details need confirmation in the periodic report.

Operating profit was KRW 95.6 billion in 2023 with a 70.6% operating margin, then turned to an operating loss of KRW 8.34 billion in 2024, a -39.9% margin. In 2025 the operating loss widened to KRW 51.8 billion, with an operating margin of -219,651.4%.

Controlling-shareholder net income moved from KRW 68.2 billion in 2023 to a controlling-shareholder net loss of KRW 5.74 billion in 2024 and KRW 42 billion in 2025.

Operating cash flow shifted from KRW 94.2 billion in 2023 to negative KRW 11.3 billion in 2024 and negative KRW 36 billion in 2025, reflecting cash used in R&D and operations.

Quarterly revenue was KRW 15.89 million in the third quarter of 2025 and KRW 0.56 million in the fourth quarter, then KRW 24.11 million in the second quarter of 2026 and KRW 24.85 million in the third quarter, up 3.1% from the prior quarter and up 56.4% from a year earlier.

Operating losses ran at KRW 13.9 billion in the third quarter of 2025, KRW 18.3 billion in the fourth quarter, KRW 18.1 billion in the first quarter of 2026, KRW 15.4 billion in the second quarter and KRW 16.1 billion in the third quarter, five consecutive loss quarters.

The controlling-shareholder net income of KRW 63.4 billion in the second quarter of 2026 came amid continued operating losses, so non-operating items may have played a role and the breakdown should be checked in the periodic report.

As a result, the four-quarter controlling-shareholder net income total of KRW 13.7 billion depends heavily on that single profitable quarter.

05

Industry analysis

Antibody-degrader conjugates (DAC) combine targeted protein degradation (TPD) with antibody delivery in place of the cytotoxic payloads of conventional ADCs, and the field is viewed as a next-generation targeted therapy with potential to overcome resistance.

No commercial product exists yet, and most programs remain in clinical development, so the outcome in this field will be decided by clinical data. Large pharma interest continues, including Roche's April 2026 technology collaboration with DAC developer C4 Therapeutics.

Orum is often described as a leader in TPD-based DAC development, yet the BMS program was expanded twice, in June 2025 and April 2026, before being discontinued in September 2026, which illustrates the uncertainty of clinical validation.

Among listed Korean biotech peers such as Alteogen, Celltrion and Samsung Biologics, larger companies have manufacturing and commercial revenue bases, whereas Orum is a small company centered on research-stage pipelines, so the difference in revenue structure and financial capacity is large.

Press reports in early 2026 described Orum as one of the cash-rich companies among KOSDAQ biotech firms ranked around the top 50 by market capitalization, but that cash must be read alongside the pace of R&D spending.

For the sector, the key variable for Orum is whether large pharma DAC partnerships translate into more signed deals. Discovery-stage assets the company has said it plans to license lack clinical data, so the timing of such deals is hard to gauge.

06

Outlook

The company has said it will keep developing its own pipeline on the DAC platform after the BMS agreement ended. The lead candidate ORM-1153 targets relapsed or refractory acute myeloid leukemia (AML) and has received IND clearance from the US FDA.

The company has also said it will pursue licensing of additional discovery-stage assets, but the stage of those assets and the timing of any deal should be confirmed through disclosures.

With BMS's decision to end development, the obligation to pay up to USD 80 million in further milestones fell away, so near-term deal income will depend on new licensing agreements.

At the end of 2025, total equity was KRW 130.9 billion and total liabilities were KRW 38.4 billion, which leaves financial room, but operating losses have continued through the third quarter of 2026, making the sustainability of R&D spending the main variable.

Press reports in early 2026 said a convertible preferred share issuance added about KRW 288.9 billion in cash, and that the funds were expected to go toward in-licensing and the company's own pipeline.

The conversion period runs from January 14, 2027 to January 13, 2031, so conversions could increase the number of shares outstanding. The next checkpoint is the 2026 annual report, where licensing deal count and R&D spending trends will provide the first formal evidence of any structural change.

The first-quarter 2027 quarterly report will show whether the operating loss narrows and how the revenue mix changes.

07

Valuation

PER
21.6×
PBR
1.7×
ROE
8.8%
EPS
₩620
BPS
₩7,975
Dividend per share
₩0

Multiples change daily with the share price. The four-quarter controlling-shareholder net income total is positive, which allows an earnings-based multiple to be calculated, but that total relies heavily on one profitable quarter in the second quarter of 2026.

The other three quarters were controlling-shareholder net losses, so an earnings-based multiple is sensitive to changes in a single quarter.

The price-to-book ratio sits in a range where investors pay a premium over net assets, and because all of total equity belongs to controlling shareholders, the net-asset comparison is straightforward. Dividend payouts are effectively absent, so a dividend-based comparison carries little meaning.

After the limit-down move in September 2026, the share price is well below its earlier trading range, so comparisons with past levels should be read against the post-adjustment base.

A quarter that moved from loss to profit is a sign of earnings recovery, but five consecutive operating-loss quarters must be weighed alongside it. How the multiple is interpreted depends on whether the emphasis is on asset value, licensing income or clinical results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Room to Rebuild the Pipeline

The company has said it will continue developing its own DAC-based pipeline after the BMS agreement ended. The blood cancer candidate ORM-1153 has IND clearance from the US FDA, so whether its clinical program produces data remains to be seen. Large pharma technology collaborations in DAC could broaden licensing opportunities for the company.

Financial Capacity and Cash Raised

On a regulatory-filing basis, total equity at the end of 2025 was KRW 130.9 billion against total liabilities of KRW 38.4 billion, so the debt burden is small relative to equity. Early-2026 press reports said a convertible preferred issuance added KRW 145 billion. The company has said the USD 100 million upfront payment from the 2023 BMS deal need not be returned.

Second-Quarter 2026 Profit Swing

Controlling-shareholder net income of KRW 63.4 billion in the second quarter of 2026 swung to profit from the prior quarter's loss. It came alongside an operating loss of KRW 15.4 billion, so the components should be checked in the periodic report. Quarterly revenue of KRW 24.85 million in the third quarter of 2026 rose 3.1% from the prior quarter.

09

Bear factors

Uncertainty in Clinical Data

The BMS program was ended after a review of clinical data, which leaves open questions about the clinical prospects of compounds built on the platform. ORM-5029 was halted during Phase 1 because of liver toxicity.

The company's own ORM-1153 is also at an early clinical stage, so its value is hard to gauge before results emerge.

Lost Milestones and an Earnings Gap

With the BMS agreement ended, up to USD 80 million in further milestones is no longer receivable. Annual operating losses have continued since 2024, and the 2025 operating loss widened to KRW 51.8 billion. Five straight quarters of operating losses suggest that an income gap could persist until new deals are signed.

Share Price Volatility and Dilution

The share price fell 29.96% on September 18, 2026, hitting the daily limit-down level, which shows high sensitivity to clinical news. Because the convertible preferred shares can be converted from January 14, 2027, the number of shares outstanding could increase. Earnings-based multiples are calculated on a four-quarter total that depends on one profitable quarter.

10

Risk factors

Clinical and Pipeline Risk

With the BMS program discontinued after a clinical data review, the burden of proving that the DAC platform can succeed clinically has grown. The solid tumor candidate ORM-5029 was halted over liver toxicity, and the blood cancer candidate ORM-1153 is at an early clinical stage. The company's direction could shift considerably depending on the results of one or two programs.

Dependence on Licensing and Revenue Gaps

Revenue has moved sharply with the timing of licensing deals. Fourth-quarter 2025 revenue was KRW 0.56 million, down 96.5% from KRW 15.89 million in the third quarter of 2025. Revenue gaps could persist for long periods when no new deals are signed.

Cash Burn and Share Dilution

Operating cash flow was negative KRW 11.3 billion in 2024 and negative KRW 36 billion in 2025. Once the conversion period starts on January 14, 2027, the number of shares could increase. The pace of cash burn should be read together with any scaling back of research programs.

11

What to watch next

  1. From January 14, 2027

    The date the conversion period for the convertible preferred shares opens. The actual conversion volume will determine the change in shares outstanding.

  2. End of March 2027

    The filing deadline for the 2026 annual report. The report will be the first to confirm full-year 2026 revenue and operating loss, along with fourth-quarter results, as formal filed figures.

  3. Mid-May 2027

    The timing of the first-quarter 2027 quarterly report. It is the point at which to check whether the operating loss narrows and whether the components of controlling-shareholder net income align with operating trends.

  4. During 2027 (timing not disclosed)

    Whether Phase 1 data for ORM-1153 is released and whether a new licensing agreement is signed. Timing remains undetermined until the company discloses a schedule.

12

Overall view

Orum's filed results show that revenue and profit fell sharply after 2023, and operating losses and controlling-shareholder net losses have continued since 2024.

The BMS decision to discontinue ORM-6151 in September 2026 ended the prospect of further milestone income, and the company has said the USD 100 million already received need not be returned.

Operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, with the second quarter of 2026 remaining a single profitable quarter within that run.

Positive factors include the company's own DAC pipeline, IND clearance for ORM-1153, and total equity of KRW 130.9 billion at the end of 2025. Negative factors include uncertainty in clinical data, the halt of ORM-5029 over liver toxicity, and the possibility of extended periods without new licensing income.

The next formal confirmation point is the 2026 annual report, where operating loss trends and the number of licensing agreements will first be reviewed. This report does not offer an investment opinion or target price, and it summarizes facts confirmed through filings and press coverage along with the next checkpoints.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. jobkorea.co.kr
  3. pharm.edaily.co.kr
  4. kpbma.or.kr
  5. biospectator.com
  6. innoforest.co.kr
  7. biospectator.com
  8. news1.kr
  9. groupby.kr
  10. news.bizwatch.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. mt.co.kr
  14. m.news.nate.com
  15. g-enews.com
  16. supple.kr
  17. m.news.nate.com
  18. press9.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis